Drawing for ASHION PMED MANAGEMENT

USPTO serial 86611153

ASHION PMED MANAGEMENT

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CHISOLM, KEVON
Law office
TMEG LAW OFFICE 103 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ASHION PMED MANAGEMENT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael J. Donovan

MICHAEL J. DONOVAN The Translational Genomics Research Institute445 N 5th St Ste 600Phoenix, AZ 85004-2274UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
044Chemical test kits for genetic testing for laboratory or research use; Assays and reagents for use in genetic research; Genetic identity tests comprised of reagents; Diagnostic preparations for scientific or research use; Nucleic acid isolation and purification kit consisting primarily of reagents for scientific research purposes; Reagents for scientific or medical research use; Testing kits comprised of medical diagnostic reagents and assays that test for the presence of certain genetic properties; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for the analysis of genetic material; Preparations for detecting mutation in prion genes for medical purposes; Clinical diagnostic preparations for medical use; Chemical reagents for medical analysis; Chemical preparation for use in medical analysis, particularly DNA analysis; Pharmaceutical preparations for diagnosis and for identifying and characterizing genetic abnormalities, tracking the progress of disease and measuring the effectiveness of immunotherapy, and for identifying and characterizing immune dysfunction; Consulting services in the field of medical education, namely, providing education and training information relating to the identification, diagnosis and treatment of medical and genetic conditions; Education services, namely, providing live and on-line continuing professional education seminars in the medical, scientific and genetics field; Education services, namely, providing training programs in the field of genetics; Conducting workshops and seminars in genetic testing and disease identification and treatment; Organization of seminars, working groups, research groups and conventions in the fields of medicine, genetics and scientific research; On-line journals, namely, blogs featuring commentary and information in the fields of DNA identification techniques, practices, and tools; Organization of conferences and symposia for the discussion, dissemination and exchange of scientific data and ideas on topics of interest to the scientific community; Providing educational demonstrations regarding biology, molecular biology, genetics, DNA sequencing and bioinformatics; Conducting educational research for others on the subjects of biology, molecular biology, genetics, genomics, DNA sequencing, and bioinformatics; Conducting classes, seminars and workshops in biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study and distributing course materials in connection therewith; Educational services, namely, conducting educational programs in biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study; Educational services, namely, conducting on-line exhibitions and displays and interactive exhibits in biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study; Organizing exhibitions for education in biology, genetics, genomics, DNA sequencing, bioinformatics and nature study; Providing courses of instruction in the fields of biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study and distributing course material in connection therewith; Teaching in the fields of biology, molecular biology, genetics, genomics, DNA sequencing and bioinformatics and nature study; Medical and scientific research in the field of genetic testing and diagnosis and treatment of medical conditions; Development and laboratory testing in the field of genetics and human disease; Scientific research consulting in the field of genetics, genomics, DNA sequencing, and bioinformatics; Consulting services in the field of pharmaceutical research and development and laboratory testing; Genetic research, development and testing services; Genomic research, development and testing services for scientific research purposes; DNA collection, testing and analysis services for scientific research purposes; Genetic testing for diagnostic purposes; Genomic testing for diagnostic purposes; Medical and scientific research, development and consulting in the field of oncology; Medical and scientific research in the field of genetics and genetic engineering; Medical and scientific research and consulting in the fields of genomics and generation sequencing; Medical and scientific research in the field of cancer treatment and diagnosis; Data collection for research purposes, namely, the collection, testing and research of patient molecular and/or genomic data; Scientific clinical studies, namely, conducting clinical trials for others; Retrieval and correlation of genomic data; Medical and scientific research relating to the design and development of cancer treatment therapies; Conducting clinical and pre-clinical trials; Diagnostic services in the field of molecular science, comparative genome analysis, DNA arrays and screening of nucleic acids; Research and development of identification and treatment methods for hereditary factors leading to disease; Identification of target molecules for cancer treatment; Proteogenomic profiling; DNA-sequencing for scientific research purposes; Targeted pharmaceutical drug development services; Genotyping; Gene screening; Gene isolation and gene expression analysis for scientific research purposes; Gene mapping; Gene analysis and biomarker discovery for scientific research purposes; Medical testing for diagnostic or treatment purposes in the field of cancer research; Medical diagnostic testing, monitoring and reporting services; Medical evaluation services; Medical monitoring services; Medical diagnostic, prognostic and theranostic screening and testing; Collection and preservation of DNA for medical and research purposes; Consulting services in the field of healthcare and cancer diagnoses; Providing a website featuring health and healthcare information related to cancer research, testing and screening; Genetic testing for medical purposes; Providing information in the field of cancer prevention, screening, diagnosis and treatment for medical diagnostic and treatment purposes; Providing genetics assessments in the nature of genetic counseling; Molecular profiling services of patients for use in providing medical and related health care services to patientsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Dec 31, 2015MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Dec 31, 2015ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 28, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 28, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 28, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 26, 2015DOCKASSIGNED TO EXAMINER—
May 8, 2015MPMKNOTICE OF PSEUDO MARK E-MAILED—
May 7, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 30, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance